ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

July 9-13, 2022. London, England, UK.

View by Title View by Number View Themes
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Abstract Number: PB0882

    Rab GTPase Protein localization, regulation and function in platelets

    N. Nguyen1, A. Melrose2, I. Parra-Izquierdo2, J. Pang2, T. Zheng2, O. McCarty3, J. Aslan2

  • Abstract Number: OC 19.1

    Rabeprazole is an Agonist of HIF-1 and Promotes Vascular Repair and Resolution of Inflammatory Lung Injury

    C. Evans1, Y. Peng1, Z. Dai2, X. Zhang1, Y. Zhao1

  • Abstract Number: PB0400

    Rac1 inhibition causes impaired GPVI signalling in human platelets through GPVI shedding and loss of PLCγ2 phosphorylation

    R. Neagoe1, D. Stegner2, B. Nieswandt3, S. Watson4, N. Poulter5

  • Abstract Number: PB0194

    Race, ethnicity and F8 mutation type influence inhibitor risk: Analysis of the “My Life Our Future” Hemophilia Database

    K. Pratt1, A. Ahmed2

  • Abstract Number: PB1087

    Rapid Detection of Exposure to Direct Oral Anticoagulants (DOACs): A Qualitative Urinary Dipstick Point-of-Care Assay

    M. Marchetti1, C. Ambaglio2, E. Sanga2, L. Barcella2, F. Schieppati2, A. Falanga3, J. Harenberg4

  • Abstract Number: PB0326

    Rapid immunoassay for platelet factor-4 in the diagnosis of vaccine-induced immune thrombotic thrombocytopenia after vaccination with ChAdOx1 nCoV-19

    G. Uzun1, K. Althaus2, S. Hammer3, Y. Wanner1, S. Nowak-Harnau1, S. Enkel1, T. Backchoul4

  • Abstract Number: PB0992

    Rare cases of acquired bleeding disorders in adolescents and young adults

    Y. Park

  • Abstract Number: PB0277

    Rate of recurrent venous thromboembolism in infants with unprovoked venous thromboembolism

    H. Whitworth1, R. Hubbard2, C. Leonard2, C. Witmer3, L. Raffini1

  • Abstract Number: PB0493

    Reach, Adoption, and Maintenance of a Population Health Dashboard for Safe DOAC Prescribing: Insights from the United States Veterans Health Affairs

    G. Barnes1, C. Chen2, P. Spoutz3, A. Allen4, J. Seagull1, J. Sussman1, M. Dorsch1

  • Abstract Number: PO0071

    Real World Data : Safety and Mortality Monitoring the patients on Rivaroxaban in our center

    F. Alayoubi1, G. Elgohary2, S. Dasuqi3, A. Hayajneh1, S. Alayoubi1

  • Abstract Number: PB0276

    Real World Data of Pediatric Thromboembolic Disease by the International Pediatric Thrombosis Network

    C. van Ommen1, M. Albisetti2, M. Bhatt3, B. Branchford4, A. Chan5, N. Goldenberg6, S. Holzhauer7, C. Male8, P. Monagle9, U. Nowak-Gottl10, S. Revel-Vilk11, G. Sciuccati12, N. Sirachainan13

  • Abstract Number: PB1145

    Real World Experience of perioperative haemostasis with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in people with Haemophilia A (PWHA)

    M. Murray1, S. Bocchinfuso2, M. O'Donovan3, E. Singleton4, J. Benson3, N. Larkin5, M. Byrne6, M. McGowan3, S. Roche3, K. Ryan4, N. O'Connell5

  • Abstract Number: PB0649

    Real world experience using rIX-FP prophylaxis in patients with haemophilia B: experience from a Spanish centre.

    O. Benítez Hidalgo1, A. de Jaureguizar Tesas2, J. Juarez Giménez1

  • Abstract Number: OC 15.3

    Real World use of Apixaban for the Prevention and Treatment of Thrombosis in Children with Cardiac and Complex Disease

    C. Vanderpluym1, P. esteso2, A. Helllinger2, C. Ventresco2, B. Hawkins2, S. O'Brien2, R. Kobayashi2, R. Williams3, M. Cetatoui2, J. Esch2

  • Abstract Number: VPB0503

    Real- world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia

    F. Alqahtani1, O. Alosaimi2, S. Alqahani2, B. Balkhi2, m. alqahtani2, F. Alzamel2, A. Alhossan3, Y. Asiri3, A. AlHarbi2, H. Albaker2

  • Abstract Number: VPB0573

    Real-life behavior of direct oral anticoagulants in the elderly population with atrial fibrillation

    B. Navarro Almenzar1, F. García-Candel2, J. Cerezo-Manchado3

  • Abstract Number: VPB0574

    Real-life behavior of direct oral anticoagulants in the population with chronic kidney disease and atrial fibrillation

    B. Navarro Almenzar1, F. García-Candel2, J. Cerezo-Manchado3

  • Abstract Number: PB0403

    Real-time assessment of inter-platelet communication and coordination of calcium signals by connexin gap junctions

    K. Taylor1, A. Bye2, J. Mitchell3, S. Ray1, J. Gibbins4

  • Abstract Number: PB0687

    Real-world efficacy of extended half-life Factor VIII in patients with haemophilia A on prophylaxis

    K. White1, J. Alamelu2, G. Ling2

  • Abstract Number: PB1130

    Real-world evidence on emicizumab in 119 Hemophilia A patients with inhibitors from the French FranceCoag cohort

    A. Harroche1, Y. Repesse2, A. Rauch3, F. HADIM4, A. Gaude5, D. Pau6, S. Pibre6, R. d'Oiron7

  • Abstract Number: OC 70.4

    Real-world management of delivery in a large cohort of haemophilia carriers: focus on maternal and neonatal outcomes.

    B. Pollio1, I. Ricca2, N. Spano3, C. Linari4, U. Ramenghi3, F. Quaglino2, R. Albiani2

  • Abstract Number: PB1031

    Real-world treatment of severe congenital protein C deficiency with protein C concentrate including prophylaxis: A physician survey in Europe and the US

    M. Wang1, C. Siffel2, P. Turecek3, H. Gazda2, S. Fung4, E. Swallow5, A. Greatsinger5, E. Billmyer5, H. Hertfelder6

  • Abstract Number: PB1163

    Real-World Unmet Needs of Patients with Haemophilia A/B with or without Inhibitors: Historical Haemophilia Characteristics from Patients Entering a Non-Interventional Study

    J. Windyga1, H. Tran2, T. Fujii3, C. Lyu4, L. Villarreal Martinez5, J. Sathar6, O. Stasyshyn7, N. Zozulya8, R. Brown Frandsen9, C. Eskelund10, S. Apte11, J. Mahlangu12

  • Abstract Number: PB1148

    Real-world usage of extended half-life FIX in a Portuguese Haemophilia Centre – prophylaxis must be for moderate and severe hemophilia B patients

    C. Peixoto1, F. Rodrigues2, A. Pereira2, S. Campaniço1, C. Correia1, P. Afonso1, J. Pestana3, L. Moura4, L. Parusnikova1, C. Catarino5

  • Abstract Number: PB0453

    Real-world Use of Andexanet Alfa for Anti-Xa Inhibitor Reversal: A Case Series

    A. Jones1, A. Brewster2, M. Jolley3, J. Saunders1, A. Wilson1, S. Vazquez1, M. Crowther4, D. Witt1

  • Abstract Number: PB0686

    Real-world use of recombinant factor IX albumin fusion protein (rIX-FP) in patients with hemophilia B: A prospective, multicenter, non-interventional post-marketing surveillance study in France

    B. Pan-Petesch1, M. Fouassier2, B. Guillet3, A. Harroche4, R. d'Oiron5, Y. Dargaud6, S. Susen7

  • Abstract Number: OC 27.4

    Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A – results from A-SURE, a 24-month prospective, non-interventional study

    J. Oldenburg1, C. Hay2, F. Peyvandi3, A. Tagliaferri4, P. Holme5, M. Alvarez-Román6, C. Biron-Andréani7, H. Malmström8, S. Lethagen8

  • Abstract Number: PB0057

    Recovery after COVID-19 and persisting Endothelial Cell Activation and Hypercoagulability- The Prospective Observational ROADMAP-Post COVID-19 Study

    P. Van Dreden1, E. Terpos2, M. Politou3, M. a.Dimopoulos2, I. Elalamy4, G. Gerotziafas5

  • Abstract Number: OC 06.2

    Recurrence risk of a first systemic lupus erythematosus-associated venous thromboembolism: a retrospective cohort study

    S. Bhoelan1, J. Borjas Howard1, V. Tichelaar1, P. van Daele2, L. Hak3, A. Voskuyl4, M. Limper5, R. goekoop6, O. Teng7, J. Vosters8, M. Bijl9, E. Zirkzee10, A. Schilder11, H. Bernelot Moens12, K. de Leeuw1, K. Meijer13

  • Abstract Number: PO0032

    Recurrent arterial thrombosis in haemophilia A

    L. Stanciakova1, P. Holly2, M. Dobrotova3, M. Brunclikova3, M. Samos4, T. Bolek4, P. Kubisz3, J. Stasko3

  • Abstract Number: OC 23.3

    Recurrent venous-thromboembolism: association with thrombin generation and D-Dimer

    E. Biguzzi1, K. Winckers2, T. Hackeng2, F. Rosendaal3, A. van Hylckama Vlieg4

  • Abstract Number: PB1363

    Red-light exposure reduces venous thrombosis in mice

    E. Andraska1, C. Kaltenmeier1, A. arivudainambi1, E. Mihalko1, M. Dyer1, S. Shea2, R. Steinman1, M. Rosengart1, M. Neal3

  • Abstract Number: PB1044

    Reference Interval of Antithrombin, Protein C, and Protein S Activities in Healthy Adults in Iran, The effect of Age, Sex, Oral Contraceptive Intake, and Menopause

    S. Tabibian1, M. Safa2, M. Khoshmirsafa3, M. Shekarabi4

  • Abstract Number: PO0018

    Reference Range Determination for the Novel T-TAS 01 AR Assay

    J. Dahlen1, A. Wu2, K. Bliden3, C. Ong2, P. Gurbel4, U. Tantry5

  • Abstract Number: PB0300

    Refractory Acquired Thrombocytopenic Thrombotic Purpura with Genetic Polymorphism Complement System

    E. Fernandes de Figueiredo1, E. Marín2, S. Ríos2, H. Sarmiento1, F. Tarín1, L. Hernández3

  • Abstract Number: OC 67.3

    Regulatory Function of the Anticoagulant Protein S in Patients with Chuvash Polycythemia

    D. Melancon1, V. Pereira2, B. Shah3, A. Sergueeva4, G. Miasnikova5, V. Gordeuk3, r. majumder6

  • Abstract Number: PB0505

    Relation among Brain Derived Neurotrophic Factor, depression, and extracellular vesicles-derived miRNA – results from an Italian cohort

    S. Barbieri1, P. Amadio1, C. Macchi2, M. Zarà1, C. Favero2, G. Solazzo2, L. Vigna3, M. Greco2, M. Buoli2, C. Siroti2, A. Ieraci2, M. Ruscica2, V. Bollati2

  • Abstract Number: VPB0314

    Relationship between recurrence of congenital and immune-mediated thrombotic thrombocytopenic purpura and mRNA-based COVID-19 vaccination: A questionnaire survey in a Japanese cohort

    E. Hamada1, M. Kubo2, K. Sakai2, S. Yamada1, M. Hayakawa2, M. Matsumoto2

  • Abstract Number: LB 01.3

    Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

    J. Mahlangu1, H. Chambost2, S. Chou3, A. Dunn4, A. von Drygalski5, R. Kaczmarek6, G. Kenet7, M. Laffan8, A. Leavitt9, B. Madan10, J. Mason11, J. Oldenburg12, M. Ozelo13, F. Peyvandi14, D. Quon15, M. Reding16, S. Shapiro17, H. Yu18, T. Robinson18, S. Pipe19

  • Abstract Number: VPB0517

    Relationship of decreased levels of omentin-1 with prothrombotic state in coronary artery disease

    O. Korzh, Y. Fylenko, S. Krasnokutskiy

  • Abstract Number: VPB0287

    Relationship of Hemostasiological Properties of Blood in Children of Different Age Groups

    a. popovicheva

  • Abstract Number: PB1021

    Renal failure-induced coagulation factor increase is similarly worsened by Haemodialysis and Haemodiafiltration

    J. Caruana1, K. Vella2, M. Cini Masini2, A. Vella2, M. Borg2, E. Farrugia3, L. Camilleri4, A. Gatt5

  • Abstract Number: VPB0419

    Renal function at enrollment but not change over time is associated with arterial thrombotic events in patients positive for lupus anticoagulant

    M. Colling1, F. Posch2, C. Ay3, S. Koder4, I. Pabinger3, J. Gebhart5

  • Abstract Number: VPB0471

    RENAL FUNCTION IMPACT IN CLINICAL AND BIOLOGIAL RESULTS FROM PATIENTS TREATED WITH DOACs IN REAL WORLD

    M. Plaza Seijas1, M. Corrochano2, S. Mojal3, C. Moret Puig4, R. Acosta-Isaac5, J. Souto6

  • Abstract Number: PO0069

    Rendu-Osler disease and recurrent thromboembolic venous disease

    R. Ben Salah1, A. Ben Mefteh2, c. Dammak3, F. Frikha4, Z. bAHLOUL5

  • Abstract Number: PO0028

    Report of clinical case: Acquired hemophilia with a high-titer inhibitor and hemorrhagic diathesis.

    R. Santoja Rubio1, A. Tugues2, E. Vicente2, C. Marzo3, P. Monteagudo4, L. Amuh4, C. Chávez5, M. Teixidó4, A. Garcia5, A. Luaña4, A. Ferrero4, A. Ruiz5, T. Garcia4

  • Abstract Number: PB0586

    Repurposing of Montelukast in COVID-19 patients in order to modulate platelet activation

    M. Brambilla1, P. Canzano1, A. Becchetti1, M. Conti2, G. Rovati3, M. Camera3

  • Abstract Number: OC 21.1

    Rescue of an FVIII splicing variant with engineered U1snRNAs

    L. Peretto1, R. Tarantino2, A. Borchiellini3, F. Bernardi4, A. Follenzi5, M. Pinotti1, D. Balestra1

  • Abstract Number: OC 12.3

    Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR/Cas9 mRNA LNPs

    C. Chen, X. Cai, C. Miao

  • Abstract Number: PB0973

    Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data

    P. Robin1, R. Le Pennec1, M. Eddy2, L. Sikora3, P. Le Roux1, M. Carrier4, F. Couturaud5, C. Tromeur6, B. Planquette7, O. Sanchez8, R. Pesavento9, M. Rodger10, M. Kovacs11, R. Mallick12, P. Salaun1, G. Le Gal13

  • Abstract Number: PB0818

    Response rate of different DDAVP dosing in Haemophilia A and von Willebrand disease

    S. Sharma1, S. Pn'g2, D. Pepperell2

  • Abstract Number: PB0797

    Restoration of VWF in Von Willebrand Disease type 3 canine ECFCs through CRISPR-Cas9 mediated gene editing

    A. Barraclough1, A. D'Amico2, R. Leite de Oliveira3, R. Bierings4, F. Leebeek5, J. Eikenboom6, S. De Meyer7, K. Vanhoorelbeke7, K. Fijnvandraat8, J. Voorberg9

  • Abstract Number: PB0012

    Restrictive versus Liberal Transfusion Strategy for Anemic Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

    R. Kou1, J. Park1, A. Li2, M. Laureano3, M. Crowther4

  • Abstract Number: PB0213

    Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients with Hemophilia B

    G. Young1, P. Chowdary2, S. Barton3, D. Yee3, F. Ferrante3

  • Abstract Number: PB1098

    Results in Patients with Heparin Induced Thrombocytopenia or Vaccine Induced Thrombocytopenia with Thrombosis Confirm the Unsuitability of Using APTT Ratio to Monitor Argatroban Therapy

    S. Platton1, C. Dale2, M. Dave2, N. Yartey2, P. MacCallum3

  • Abstract Number: PB0307

    Results of a Single-centre Targeted Screening Approach to Identify Potential Occult Cases of Pregnancy-associated Thrombotic Thrombocytopenic Purpura (TTP).

    L. Neave1, M. Thomas2, C. Vendramin3, K. Maksym4, R. Spencer5, A. David6, A. Doyle7, M. Whitten8, M. Scully9

  • Abstract Number: PB1092

    Results of samples spiked with chimeric monoclonal anti-PF4 antibody 1C12 in ECAT external quality assessment surveys for heparin-induced thrombocytopenia diagnosis.

    P. Meijer1, J. Rollin2, G. Champier3, C. Vayne2, Y. Gruel2, C. Pouplard4

  • Abstract Number: PB0182

    Results of the implementation of home management in times of the covid-19 pandemic in patients with hemophilia A in Colombia

    S. Sarmiento1, G. Diaz Mosquera2, J. cortes3, C. Agudelo Rico4, J. Peña Siado2, N. Ramirez Plazas2, A. Parrado Rey2, F. Meza Cadavid2, C. Montaño Mejía5, A. Maza Villadiego2, I. Perdomo Amar5

  • Abstract Number: PB1088

    Results of the thrombin time test obtained with two different commercial reagents in real life patients treated with dabigatran

    A. Bronic1, S. Margetic2, E. Esmat3, B. Dejan4, C. Tomislav4, I. Bencic4, D. Vidovic4

  • Abstract Number: PB0667

    Results of thromboelastography and thrombin generation assays for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes

    N. Mathews1, F. Pluthero2, M. Rand3, A. Stain2, M. Carcao4, V. Blanchette3, W. Kahr3

  • Abstract Number: PB0172

    Results of thromboelastometry and thrombin generation assays for emicizumab prophylaxis monitoring

    S. Arcudi1, M. Clerici2, E. Scalambrino3, R. Gualtierotti4, C. Novembrino5, A. Truma6, A. Ciavarella7, S. Siboni3, E. Biguzzi2, A. Tripodi2, F. Peyvandi8

  • Abstract Number: PB0459

    Retrieval rate and complications of inferior vena cava filters placed during acute venous thromboembolism.

    D. Santagata1, W. Ageno2, M. Venturini3, M. Donadini4, F. Fontana3, F. Piacentino3

  • Abstract Number: PB1161

    Retrospective analysis of treatment individualization on hemophilia B patients from two Spanish centers who switched from SHL-FIX products to rIX-FP

    A. Tugues1, E. Vicente1, R. Santoja2, A. Marco3, P. Marco Vera4, M. Gilabert5, J. Rius5, I. Mangues5, I. Delgado2, A. Ruiz6, A. Garcia6, C. Chávez6, M. Teixidó7, E. Rivero2, A. Luaña7, A. Ferrero2, T. Garcia7, C. Marzo8

  • Abstract Number: VPB0280

    Retrospective Case Series Study of patients with May-Thurner Syndrome in a single Tertiary Pediatric Center

    J. Brauner, R. Aneja, S. Yilmaz, J. Cooper, F. Xavier

  • Abstract Number: PB0811

    Retrospective Cohort Study of GPIbM and D1472H in Patients Referred for Von Willebrand Disease Testing

    D. Dulak1, N. Machin1, F. Xavier1, C. Seaman2, M. Ragni1

  • Abstract Number: OC 55.1

    Retrotransposon insertions: a challenging detection and characterization solved by long-read nanopore sequencing. Relevance in antithrombin deficiency

    B. de la Morena-Barrio1, J. Cuencia-Guardiola2, P. Garrido-Rodríguez3, A. Sanchis-juan4, M. de la Morena-Barrio3, R. Cifuentes-Riquelme3, C. Bravo-Pérez5, J. Padilla6, A. Miñano5, F. vidal7, M. Lozano3, W. Ouwehand8, J. fernández-breis2, J. Corral3

  • Abstract Number: PB1012

    Review of a Peri-operative mobile application to conform anticoagulation management and review of safety and clinician satisfaction.

    J. Ruell1, M. Thorpe1, D. Fathoala2, S. Allford1

  • Abstract Number: VPB0795

    Reviewing atypical Hemolytic Uremic Syndrome in a portuguese terciary hospital

    M. Afonso, R. Almeida Dias, A. Barbosa, A. Marques

  • Abstract Number: VPB1422

    Revision of the diagnostic methods used for the detection of pulmonary embolism in pregnant women at the Centre Hospitalier Universitaire de Sherbrooke

    M. Patterson1, G. Le Templier1, L. Savoie2

  • Abstract Number: PB1037

    Rewarming from accidental hypothermia enhances whole blood coagulation in a mouse model

    K. Horioka1, H. Tanaka2

  • Abstract Number: PB0353

    RhoB drives megakaryocyte transendothelial migration in RhoA-deficient mice

    M. Englert1, K. Aurbach1, T. Heib2, I. Becker3, L. Wackerbarth4, C. Kusch5, U. Knaus6, C. Stigloher7, I. Pleines1, B. Nieswandt1, Z. Nagy8

  • Abstract Number: OC 59.2

    Ribosomal biogenesis inhibition facilitates megakaryocyte/platelet biased haematopoiesis

    V. Bhoopalan1, A. Kaur2, N. Hein2, K. Maclachlan3, R. Ferreira2, S. Man2, R. Hannan2, K. Hannan2, E. Gardiner4

  • Abstract Number: PB0968

    Right heart thrombus and pulmonary embolism: early diagnosis and therapeutic management

    N. Diaconu, T. Cuzor

  • Abstract Number: OC 52.2

    Risk and impact of anticoagulation-associated abnormal menstrual bleeding in women of reproductive age with venous thromboembolism – the TEAM-VTE study

    C. De Jong1, M. Blondon2, C. Ay3, A. Buchmuller4, J. Beyer Westendorf5, J. Biechele6, L. Bertoletti7, G. Colombo8, M. Donadini9, S. Hendriks10, L. Jara-Palomares11, S. Nopp12, P. Ruiz-Artacho13, P. Stephan14, C. Tromeur14, T. Vanassche15, P. Westerweel16, F. Klok1

  • Abstract Number: OC 61.1

    Risk factors for bleeding after recent medical hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)

    M. Gergi1, K. Wilkinson2, A. Sparks1, H. Al-Samkari3, N. Smith4, N. Roetker5, T. Plante6, M. Cushman7, A. Repp1, C. Holmes8, N. Zakai9

  • Abstract Number: PB0676

    Risk factors for bleeding in people living with Hemophilia A and B treated with regular prophylaxis: a systematic review of the literature.

    F. Germini1, N. Noronha2, A. Binu2, O. Olasupo2, D. Pete2, T. Navarro2, A. Keepanasseril1, D. Matino1, K. de Wit3, S. Parpia2, A. Iorio1

  • Abstract Number: VPB0998

    Risk factors for intracranial hematomas during anticoagulant therapy

    N. Vorobyeva1, A. Shapkov2

  • Abstract Number: PB0915

    Risk Factors of Venous Thromboembolism among Elderly Patients with Acute Myeloid Leukemia by Race in the United States

    A. Faiz, C. Philipp

  • Abstract Number: PB1352

    Risk Factors of Venous Thromboembolism in Patients with Varicose Disease of the Lower Extremities

    O. Atamanyuk, V. Atamaniuk

  • Abstract Number: PB0501

    Risk of anticoagulant-related nephropathy early after initiating treatment

    G. Tratar1, T. Vižintin Cuderman2, A. Škoberne3, A. Koželj4, V. Lapuh4, L. Rozman4

  • Abstract Number: PB1368

    Risk of bleeding and venous thromboembolism in patients using therapeutic dosage of Direct Oral Anticoagulants undergoing total hip or total knee arthroplasty

    M. Smeets1, E. Kristiansen2, B. Nemeth3, M. Huisman4, S. Cannegieter1, A. Pedersen2

  • Abstract Number: OC 14.3

    Risk of long-term mortality in elderly patients with venous thrombosis

    H. Wang1, F. Rosendaal2, A. van Hylckama Vlieg3

  • Abstract Number: PB0458

    Rivaroxaban for management of Superficial Vein Thrombosis

    M. Rees1, R. Cloudsdale2, S. Bladen2, R. Alikhan2, D. Gosrani2

  • Abstract Number: PB0270

    Rivaroxaban for the treatment of thrombosis in pediatric patients with leukemia. Results of a pilot study

    S. Rodriguez Miranda1, J. Colunga Pedraza2, L. Villarreal Martinez3, M. Zazueta Martinez4, S. Ramirez Cortinas4, L. Hernandez Torres4, S. Fierro Saenz4, H. Ramirez Duran4, G. Aliaga Orellana4

  • Abstract Number: PB1372

    Rivaroxaban in patients with intestinal failure on parenteral nutrition (TINCRBEL study)

    T. van Haaps1, R. Bavalia2, R. Mathôt3, M. Serlie4, S. Middeldorp5, M. Coppens6

  • Abstract Number: OC 54.1

    Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer

    C. Becattini1, U. Pace2, F. Pirozzi3, A. Donini4, G. Avruscio5, F. Rondelli6, M. Boncompagni7, D. Chiari8, M. De Prizio9, A. Visonà10, R. De Luca11, F. Guerra12, A. Muratore13, G. Portale14, M. Righini15, S. Frasson16, F. Dentali17, P. Del Rio2, G. Gussoni16, G. Agnelli18

  • Abstract Number: PB1265

    Role of a cellular antiprotease named Protease-Nexin-1 in the development of atherosclerosis

    C. Madjene1, Y. Boulaftali2, V. Arocas2, S. Loyau3, B. Ho-Tin-Noé4, M. Bouton2

  • Abstract Number: VPB1140

    Role of activated platelets in compensation of bleeding severity in Hemophilia A

    C. Laha Roy1, S. Maharana1, K. Kishor2, R. Ranjan2, M. Mahapatra3, R. Saxena4, M. Kannan1

  • Abstract Number: OC 09.5

    Role of disturbed blood flow in the intrinsic thrombogenicity of human carotid stents

    A. KERN1, Y. Kreinin2, R. Pop3, N. Korin2, P. Mangin4

  • Abstract Number: OC 07.1

    Role of GABARAP protein in the intracellular distribution of FVIII

    S. El-Hazzouri1, H. Singer1, M. Ibrahim1, N. Nüsgen1, J. Oldenburg2, O. El-maarri1

  • Abstract Number: PB1252

    Role of matrix Gla protein in vascular calcification: hard chemistry for soft vessels

    S. Agten1, D. Suylen2, A. Gentier3, L. Schurgers2, T. Hackeng2

  • Abstract Number: PB0623

    Role of Transglutaminase 2 in Haemostasis and as a Novel Treatment Option for Acquired Autoimmune Factor XIII Deficiency

    B. Li1, R. Suzuki1, M. Golomingi1, K. Hitomi2, V. Schroeder1

  • Abstract Number: PB0725

    Role of von Willebrand factor Antigen as Non-invasive Biomarker for the Prediction of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis

    M. El Horri1, F. El Horri2, A. Chikh Khelifa3, M. Chekkal4, K. Benbouhadi1, H. Mimene1, K. Kebir1, K. Benhalima1, A. Benglia1, L. Benmahdi1, H. BROUK5

  • Abstract Number: LB 02.5

    Roles of FVIII in endothelial cell biology more than a coagulation factor

    c. olgasi1, A. Cucci2, S. Assanelli2, C. Sgromo2, C. Borsotti2, G. Walker2, I. Molineris3, F. Anselmi3, S. Oliviero3, A. Follenzi4

  • Abstract Number: PB0330

    Romiplostim (Nplate) Use for Thrombocytopenia at a Large Academic Medical Center

    A. Wong, E. Xiang, F. Cirrone, J. Papadopoulos, T. Ahuja

  • Abstract Number: PB1241

    Rotational thromboelastometry (ROTEM) in patients with bleeding of unknown cause: evidence for hemostatic imbalance

    D. Mehic1, B. Jilma2, C. Schörgenhofer2, M. Colling1, C. Ay3, I. Pabinger3, J. Gebhart4

  • Abstract Number: PB0062

    Rotational thromboelastometry in heparin monitoring in critical COVID-19 disease.

    L. Schulting1, A. Hulshof2, M. Mulder3, J. Sels3, H. ten Cate4, I. van der Horst5, B. van Bussel6, Y. Henskens7

  • Abstract Number: PB1071

    Routine Measurement of Direct Factor Xa Inhibiting Anticoagulants

    M. Dave1, C. Dale1, L. Fayehun-Idowu2, K. Mahadevan3, N. Yartey1, S. Platton4

Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley